Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 4Gemcitabine 3Biopsy 3eribulin 2cabozantinib 2atezolizumab 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1carotuximab 1avelumab 1Watchful Waiting 1Platinum 1Observation 1Nivolumab 1Lenalidomide 1Ipilimumab 1Interleukin-7 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Contrast Media 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bortezomib 1Bevacizumab 1Arsenic Trioxide 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ureteral Neoplasms × Contrast Media × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡